Home › Breast Cancer › Georgia
Breast Cancer clinical trials in Georgia
52 studies for Breast Cancer are looking for participants at sites in Georgia.
Cities in Georgia
- Atlanta42 studies
- Savannah12 studies
- South Fulton6 studies
- Athens5 studies
- Augusta5 studies
- Johns Creek4 studies
- Sandy Springs3 studies
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
- Grady Memorial Hospital, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07748208Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
- Emory University School of Medicine, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT05696626A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Summit Cancer Care, Savannah
RecruitingPhase 1
Ages 18 to 55 · Women · Updated Nov 12, 2026 · NCT07310420S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Northside Hospital, Atlanta
- Northeast Georgia Medical Center-Gainesville, Gainesville
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT03418961Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Research Facility, Atlanta
RecruitingPhase 1/2
All ages · All sexes · Updated Nov 12, 2026 · NCT06590857A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
- University Cancer & Blood Center, LLC, Athens
- Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06827236A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
- City of Hope Cancer Center - Atlanta ( Site 0102), Newnan
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06966700Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
- Atlanta Cancer Care - Northside Hospital, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06982521A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- University Cancer & Blood Center, LLC, Athens
- Piedmont Columbus Regional - John B. Amos Cancer Center, Columbus
- Central Georgia Cancer Care, Macon
- and 3 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07174336A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
- Northwest Georgia Oncology Centers PC - Marietta, Marietta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06790693E-Mindfulness Approaches for Living After Breast Cancer
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- and 4 more
RecruitingPhase 3
Ages 18 to 50 · All sexes · Updated Nov 4, 2026 · NCT06748222A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
- Winship Cancer Institute, Atlanta
- City of Hope National Medical Center, Atlanta Cancer Center, Newnan
RecruitingPhase 2
Ages 18 and older · Women · Updated Nov 4, 2026 · NCT07287098Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Northeast Georgia Medical Center Braselton, Braselton
- Atlanta VA Medical Center, Decatur
- Northeast Georgia Medical Center-Gainesville, Gainesville
- and 4 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Augusta University Georgia Cancer Center, Augusta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT05579366Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Northside Hospital, Atlanta
- John B Amos Cancer Center, Columbus
- Northside Hospital - Duluth, Duluth
- and 5 more
RecruitingObservational study
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06418204A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06400472A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Emory University School of Medicine - Winship Cancer Institute, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07114601Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
- Phoebe Putney Memorial Hospital, Albany
- University Cancer and Blood Center LLC, Athens
- Grady Health System, Atlanta
- and 17 more
RecruitingPhase 3
Ages 18 to 60 · Women · Updated Nov 4, 2026 · NCT05879926The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
- Emory University Winship Cancer Institute, Atlanta
- Liberty County Cancer Care, Hinesville
- Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite, Pembroke
- and 2 more
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Nov 2, 2026 · NCT06377852Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT07288359A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
- Emory University Hospital, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT05646862A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
- Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT07100106Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Emory University - Winship Cancer Institute, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06582017A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer
- Research Site, Marietta
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Oct 19, 2026 · NCT07647328A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital, Atlanta
- Investigational Drug Service Emory University Clinic, Atlanta
- and 4 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 19, 2026 · NCT07062965Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Georgia Cancer Center at Augusta University, Augusta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06293898A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06369285Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
- Emory Proton Therapy Center, Atlanta
RecruitingPhase 3
Ages 19 and older · Women · Updated Sep 29, 2026 · NCT05856773Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
- Clinical Trial Site, Marietta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07085767A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
- Emory University (Data Collection Only), Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05570253Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
- Emory University, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT05846789Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Winship Cancer Institute of Emory University, Atlanta
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06072612A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
- Augusta University, Augusta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06764940Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya
- Emory University Hospital/Winship Cancer Institute, Atlanta
RecruitingHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Aug 14, 2026 · NCT07764796FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
- Emory University, Atlanta
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT05304962Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
- Winship Cancer Institute at Emory University, Atlanta
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06263543A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
- Northside Hospital, Atlanta
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 10, 2026 · NCT06926868Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
- City of Hope - Cancer Center Atlanta, Newnan
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Aug 6, 2026 · NCT05232916First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 7, 2026 · NCT05768139A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
- Winship Cancer Institute, Emory University, Atlanta
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05377996From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.